Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Cash from Operations (2016 - 2026)

Champions Oncology has reported Cash from Operations over the past 17 years, most recently at 1339000.0 for Q1 2026.

  • For Q1 2026, Cash from Operations fell 373.27% year-over-year to 1339000.0; the TTM value through Jan 2026 reached 4394000.0, up 438.52%, while the annual FY2025 figure was 7386000.0, 220.35% up from the prior year.
  • Cash from Operations for Q1 2026 was 1339000.0 at Champions Oncology, up from 1735000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 6868000.0 in Q2 2025 and troughed at 3991000.0 in Q3 2023.
  • A 5-year average of 458823.53 and a median of 311000.0 in 2024 define the central range for Cash from Operations.
  • Biggest five-year swings in Cash from Operations: soared 3053.33% in 2022 and later crashed 1946.67% in 2023.
  • Year by year, Cash from Operations stood at 3286000.0 in 2022, then tumbled by 82.08% to 589000.0 in 2023, then crashed by 148.05% to 283000.0 in 2024, then crashed by 513.07% to 1735000.0 in 2025, then grew by 22.82% to 1339000.0 in 2026.
  • Business Quant data shows Cash from Operations for CSBR at 1339000.0 in Q1 2026, 1735000.0 in Q4 2025, and 600000.0 in Q3 2025.